Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
Research Use Only: All products are intended exclusively for laboratory and scientific research
Importantly, this proof-of-concept study showed that the relative abundance of Lactobacillus , a genus associated with weight loss 58 , was uniquely increased and Erysipelatoclostridium was distinctly decreased in mice given 5A-1MQ treatment and an LD switch compared to mice switched to LD and given vehicle treatment
The link with overall death rates was much less consistent
We encourage all patients to discuss current regulatory status with our providers during consultation
US$ 22.07
US$ 27.10
US$ 29.21
US$ 29.27
